Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis ​​on the management of SE

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California.

Presentation details are as follows:

Podium Presentation Details:

Thursday, October 17, 2024, 9:35-9:55 a.m. PT

  • Title: Efficacy and Safety of Intravenous Ganaxolone for Treatment of Refractory Status Epilepticus: Results from the Phase 3, Double-Blind, Randomized, Placebo-Controlled RAISE Trial
  • Presenting Author: Brandon Foreman, M.D., M.S., FACNS, FNCS, Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery at the University of Cincinnati and Associate Director for Neurocritical Care Research
  • Session: Late-Breaking Science Oral Platform

Poster Presentation Details:

Wednesday, October 16, 2024, 2:45-3:45 p.m. PT

  • Title: High Rate of Interhospital Transfers in Status Epilepticus: Challenges in Management of Care
  • Presenting Author: Henrikas Vaitkevicius, M.D., VP, Clinical Development, Marinus Pharmaceuticals
  • Session: Poster Session Day 2

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U.S. in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

Investors Sonya Weigle Chief People and Investor Relations Officer Marinus Pharmaceuticals, Inc. sweigle@marinuspharma.com Media Molly Cameron Director, Corporate Communications & Investor Relations Marinus Pharmaceuticals, Inc. mcameron@marinuspharma.com

Marinus Pharmaceuticals (NASDAQ:MRNS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Marinus Pharmaceuticals
Marinus Pharmaceuticals (NASDAQ:MRNS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Marinus Pharmaceuticals